TORONTO, Sept. 4 /CNW/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading
provider of products and services to the global life-sciences markets, today
announced that the Company has scheduled a Special Meeting of Shareholders to
seek approval of the proposed sale of MDS Analytical Technologies to Danaher
Corporation (NYSE: DHR). The meeting, which will commence at 4 p.m., will be
held on October 20, 2009 at the Toronto Congress Centre.
The record date for the purpose of determining shareholders entitled to
receive notice of, and to vote at, the Special Meeting is September 14, 2009.
The MDS Board of Directors believes the proposed sale of MDS Analytical
Technologies to Danaher is in the best interests of the Company and its
shareholders, and unanimously recommends that shareholders vote in favor of
MDS expects that a Management Proxy Circular for the shareholder meeting
will be mailed to shareholders later this month and will be available at
www.sedar.com, www.sec.gov/edgar.shtml and www.mdsinc.com. The Management
Proxy Circular will provide important information about the proposed
transaction as well as information related to voting procedures.
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that
provides market-leading products and services that our customers need for the
development of drugs, and the diagnosis and treatment of disease. We are a
leading global provider of pharmaceutical contract research, medical isotopes
for molecular imaging, radiotherapeutics, and analytical instruments. MDS has
more than 4,200 highly skilled people in 13 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
For further information: MEDIA: Janet Ko, (905) 267-4226,
email@example.com; INVESTORS: Kim Lee, (905) 267-4230, firstname.lastname@example.org